Compare · MRK vs TEVA
MRK vs TEVA
Side-by-side comparison of Merck & Company Inc. (MRK) and Teva Pharmaceutical Industries Limited (TEVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and TEVA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $295.19B, about 7.6x TEVA ($38.73B).
- TEVA has been more active in the news (30 items in the past 4 weeks vs 27 for MRK).
- Both have 25 recent analyst ratings on file.
- Company
- Merck & Company Inc.
- Teva Pharmaceutical Industries Limited
- Price
- -
- -
- Market cap
- $295.19B
- $38.73B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 27
- 30
- Recent ratings
- 25
- 25
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Latest MRK
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Russo Patricia F
- SEC Form 4 filed by Director Rothman Paul
- SEC Form 4 filed by Director Mayo Stephen
Latest TEVA
- Director Barer Sol J converted options into 21,739 units of Ordinary Shares, increasing direct ownership by 5% to 448,011 units (SEC Form 4)
- Director Lichtenstein Chen converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 302% to 19,296 units (SEC Form 4)
- Director Crane Rosemary A converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 13% to 127,739 units (SEC Form 4)
- Director Elstein Amir converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 0.69% to 2,118,455 units (SEC Form 4)
- Director Lieberman Gerald M converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 13% to 130,149 units (SEC Form 4)
- Director Nisen Perry converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 14% to 119,807 units (SEC Form 4)
- Director Satchi-Fainaro Ronit converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 15% to 112,401 units (SEC Form 4)
- Director Zaks Tal Zvi converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 25% to 73,264 units (SEC Form 4)
- Director Mignone Roberto converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 14% to 119,807 units (SEC Form 4)
- President and CEO Francis Richard D converted options into 13,043 units of Ordinary Shares and sold $211,356 worth of Ordinary Shares (6,153 units at $34.35) as part of a pre-agreed trading plan, increasing direct ownership by 0.59% to 1,177,529 units (SEC Form 4) (tax liability)